Physician survey of 84 endocrinologists and primary care physicians on their impressions and expected use of Amylin's and Alkermes's Bydureon (once-weekly exenatide)
On January 27, 2012, the FDA approved Amylin's and Alkermes's Bydureon (once-weekly exenatide) for adults with type 2 diabetes. This survey shows broad enthusiasm for the drug among endocrinologists and PCPs, but initial excitement may wane as physicians fully weigh such factors as comparative efficacy with Novo Nordisk's Victoza (liraglutide), injection device size and convenience, and cost.
FEATURES AND BENEFITS
- Physicians were asked to assess their impressions of Bydureon in terms of efficacy, safety, tolerability, expected use, and other important factors
- Key questions are broken down by specialty or familiarity to highlight difference in physician perceptions
- Datamonitor anticipates that the initial enthusiasm will ultimately be muted once physicians gain experience with the drug. Nevertheless, a once-weekly antidiabetic agent clearly represents an attractive option for type 2 diabetes patients, and physicians expect the drug to be a welcome addition to their armamentarium.
YOUR KEY QUESTIONS ANSWERED
- Assess physicians' opinions of Bydureon as compared with Amylin's twice-daily Byetta (exenatide) and Novo Nordisk's once-daily Victoza (liraglutide)
- Determine physicians' expectations for Bydureon's uptake, line of therapy, and use in combination with other antidiabetics
- Evaluate how Bydureon may expand the overall market for GLP-1 agonists
BYDUREON FDA APPROVAL: PHYSICIAN OPINION
- Limited familiarity with PCPs could present a marketing challenge
- Impressions of Bydureon's efficacy differ based on familiarity
- Tolerability issues trump safety concerns among physicians familiar with Bydureon
- High expectations for Bydureon use will likely come down with increased experience
- Endocrinologists expect to use Bydureon in earlier line of therapy compared to PCPs
- Combination use with oral antidiabetics is likely
- Physicians expect Bydureon to expand the GLP-1 agonist market
- Report methodology
- Datamonitor consulting
- Figure: On average, how many patients with type 2 diabetes do you treat per month?
- Figure: How familiar are you with Bydureon (once-weekly exenatide)?
- Figure: For each attribute below, please select the one drug that you would prefer to prescribe, based on performance (or predicted performance) on that attribute
- Figure: Please select the one drug that you would prefer to prescribe, based on efficacy (HbA1c lowering ability)
- Figure: Please rank the following potential safety (and tolerability) issues you are most concerned about with Bydureon on a scale of 1 to 7, where 1 is the issue of greatest concern and 7 is the issue of least concern
- Figure: Please select the one drug that you would prefer to prescribe, based on injection device
- Figure: Where in the treatment algorithm do you think you will most commonly prescribe Bydureon?
- Figure: Please consider your hypothetical Bydureon-treated patient population a year post-launch. What percentage of the Bydureon-treated patient population do you expect to have previously been treated with each of the following options?
- Figure: Please choose up to three drug classes with which Bydureon could be used in combination. If there are more than three classes, please select the three most likely
- Figure: Please give your opinion on how the introduction of Bydureon, and any other market trends, will impact on the number of patients on GLP-1 agonists in the US